Log in

NASDAQ:EVOKEvoke Pharma Stock Price, Forecast & News

$3.47
-0.11 (-3.07 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.44
Now: $3.47
$3.56
50-Day Range
$2.04
MA: $2.85
$3.80
52-Week Range
$0.73
Now: $3.47
$5.00
Volume366,290 shs
Average Volume816,378 shs
Market Capitalization$85.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Read More
Evoke Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.18 per share

Profitability

Net Income$-7,130,000.00

Miscellaneous

Employees6
Market Cap$85.72 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

How has Evoke Pharma's stock been impacted by COVID-19 (Coronavirus)?

Evoke Pharma's stock was trading at $1.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EVOK stock has increased by 212.6% and is now trading at $3.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evoke Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evoke Pharma.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Evoke Pharma.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) issued its quarterly earnings data on Tuesday, May, 12th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. View Evoke Pharma's earnings history.

What price target have analysts set for EVOK?

1 brokerages have issued 1 year target prices for Evoke Pharma's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Evoke Pharma's share price to reach $10.00 in the next year. This suggests a possible upside of 188.2% from the stock's current price. View analysts' price targets for Evoke Pharma.

Has Evoke Pharma been receiving favorable news coverage?

Press coverage about EVOK stock has been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evoke Pharma earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Evoke Pharma.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in June. As of June 30th, there was short interest totaling 309,700 shares, an increase of 13.8% from the June 15th total of 272,200 shares. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is presently 0.2 days. Approximately 1.4% of the shares of the company are sold short. View Evoke Pharma's Current Options Chain.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the following people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $3.47.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $85.72 million. The specialty pharmaceutical company earns $-7,130,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Evoke Pharma employs 6 workers across the globe.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is www.evokepharma.com.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.